Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05124210 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05124210 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 8 participants.
The verdict
NCT05124210, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (\<)18 years old with mild-to-moderate Coronavirus Disease-2019 (COVID-19) at high risk of disease progression.
Interventions
- BIOLOGICAL Sotrovimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05124210
The ClinicalTrials.gov registry entry for NCT05124210 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sotrovimab is the first listed.
NCT05124210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05124210 about?
NCT05124210 is a clinical study titled "Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19". This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (\<)18 years old with mild-to-moderate Coronavirus Disease-2019 (COVID-19) at high risk of disease progression.
What is the current status of trial NCT05124210?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2021-12-16. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT05124210?
The interventions under investigation include: Sotrovimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05124210?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.